scyllo-Inositol, preclinical, and clinical data for Alzheimer's disease.

Abstract

Preclinical development of scyllo-inositol for the treatment of Alzheimer's disease (AD) has been investigated in both in vitro and in vivo models with positive results. scyllo-Inositol stabilized a small conformer of Aβ42 in vitro, neutralized cell derived Aβ trimers and promoted low molecular weight Aβ species in vivo. These interactions resulted in decreased neuronal toxicity, increased long-term potentiation (LTP) and ablation of cognitive deficits in multiple mouse models of AD. scyllo-Inositol bioavailability, pharmacokinetics, and small animal toxicology studies demonstrated the potential for translation to human patients. The results of Phase I and Phase II clinical trials for AD are presented. Furthermore, the use of this compound for imaging and other amyloid related disorders is discussed.

• Authors: Keran Ma, Lynsie A M Thomason, JoAnne McLaurin
• Journal: Advances in pharmacology (San Diego, Calif.) (Adv Pharmacol) Vol. 64 Pg. 177-212 ( 2012) ISSN: 1557-8925 [Electronic] United States
• PMID: 22840748 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2012 Elsevier Inc. All rights reserved.

Chemical References

• scyllitol
• Inositol

Topics

• Alzheimer Disease (drug therapy, pathology)
• Animals
• Biological Availability
• Clinical Trials as Topic
• Drug Evaluation, Preclinical
• Humans
• Inositol (pharmacokinetics, therapeutic use)
• Structure-Activity Relationship